Business Wire

Jamaica Boosting Its Energy Industry

9.8.2021 21:30:00 EEST | Business Wire | Press release

Share

The Caribbean’s leader in renewable energy, Jamaica, is making significant strides in boosting the diversification of its energy sector, as the government looks to implement the island’s ambitious Integrated Resource Plan (IRP).

The initiative has set a goal of adding around 1,600 megawatts (MW) of generation capacity over the next 20 years to expand the island’s energy resources. The aim is to facilitate reduced energy prices, and decrease vulnerability of the energy sector to external shocks such as oil prices. The IRP creates business opportunities in the form of requests for proposals (RFPs) that seek investors to fulfill the demand for more energy generation.

The IRP’s targets include 1260 MW of wind and solar, 330 MW of liquid natural gas (LNG), and 74 MW of hydro, biomass or waste energy by the year 2037. JAMPRO, Jamaica’s investment promotions agency, is tasked with securing the local and foreign investment that will drive the plan’s success, and the achievement of these targets.

The island is well on its way. Jamaica wants to have 33 per cent of electricity generation from renewables by 2030, and there are already impressive renewable energy projects on the island that are proving to be a strong foundation for the country’s energy resource plan. The 20-megawatt (MW) Content Solar Ltd. solar energy electricity generation plant owned by WRB Energy Company in Clarendon is one such example. In Westmoreland, the largest photovoltaic power plant in Jamaica, the 51 MWp (megawatts-peak) Paradise Park solar farm, is one of the island’s cheapest producers of energy.

There is also the Wigton Windfarm in Rose Hill, Manchester, which is the largest facility of its kind in the Caribbean with a 20.7 MW plant and an 18 MW extension facility. Jamaica’s energy provider, the Jamaica Public Service (JPS)’s Munro Wind Farm has a 3 MW capacity, while Blue Mountain Renewable (BMR) Jamaica Wind generates 34 MW. In St. Elizabeth, the JPS utility company operates a 7.2 MW hydro-electric plant in Maggoty.

Regarding these projects, Don Gittens, JAMPRO’s Manager of Logistics, Energy, and Infrastructure, stated “Current renewable energy projects represent approximately 14 per cent of energy generation in Jamaica, but our target is 50 per cent. There is therefore a significant opportunity because we have that gap between 14 per cent and 50 per cent that we intend to fill with additional renewable energy investments.”

Jamaica is currently seeking to procure 320 MW of wind and solar, 120 MW of LNG and 74 MW of hydro, biomass or waste energy for this year. Gittens elaborated, “That is the opportunity that exists right now for investors, so, these are very exciting times.”

Interest high in Jamaica’s energy sector

According to JAMPRO, there is serious interest in Jamaica’s energy sector. The Agency is entertaining several local and international investors who are interested in partaking in the RFP that is to come with the aforementioned energy generation opportunities.

This interest was maintained by JAMPRO through the pandemic, as the organisation chose to intensify its marketing activities. The company increased its digital outreach and direct engagements with sector leaders and business executives locally and internationally.

Diane Edwards, President of JAMPRO, said, “While there was a feeling of uncertainty, especially at the beginning of the pandemic, we knew that we had to continue to nurture our relationships and the renewable energy opportunity in Jamaica, and increase our marketing activities. COVID-19 re-emphasised the fact that sectors like logistics, energy, and agriculture must be major priorities, so the Jamaican government really used this time to identify the areas that needed even more focus as we continue Jamaica’s development.”

Sector development initiatives have continued, and JAMPRO has partnered with entities like New Energy Events and the REA - The Association for Renewable Energy & Clean Technology in the UK to continue its global promotion of the energy industry. Jamaica has also begun work on the development of an electronic vehicle charging network, confirming the country’s commitment to alternative energy sources.

“This is a very exciting time within the local and global energy sector as everything is moving towards renewable energy,” Gittens enthused. “Once the RFPs are ready, we are confident there will be a lot of investment coming through.”

ABOUT JAMPRO

The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.

For more information on JAMPRO, please visit https://dobusinessjamaica.com/.

Follow us on:

Twitter
Facebook
Instagram
LinkedIn

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Integrated Marketing Communications
Tamica Parchment
tparchment@jamprocorp.com
Tele: 876-978-7755

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release

Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release

WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release

Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye